

Bernard Royer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3056030/publications.pdf>

Version: 2024-02-01

18
papers

244
citations

1040056

9
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

262
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 3322-3334.	1.5	3
2	Exposure-response analysis of Raltitrexed assessing liver toxicity. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1327-1337.	2.4	5
3	Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 229-239.	2.3	4
4	Population Pharmacokinetics of Palbociclib in a Real-World Situation. <i>Pharmaceuticals</i> , 2021, 14, 181.	3.8	4
5	Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. <i>Pharmaceutics</i> , 2021, 13, 1708.	4.5	8
6	A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1132, 121844.	2.3	34
7	A simple and fast LC-MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1060, 240-246.	2.3	3
8	Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 156, 199-203.	1.1	4
9	Level of evidence for therapeutic drug monitoring of taxanes. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 414-424.	1.9	12
10	Level of evidence for therapeutic drug monitoring for etoposide after oral administration. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 277-282.	1.9	5
11	Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study. <i>Anti-Cancer Drugs</i> , 2010, 21, 320-325.	1.4	13
12	An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. <i>Journal of Mass Spectrometry</i> , 2010, 45, 670-677.	1.6	29
13	Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Perioperative Administration. <i>Clinical Pharmacokinetics</i> , 2009, 48, 169-180.	3.5	11
14	The Authors' Reply. <i>Clinical Pharmacokinetics</i> , 2009, 48, 686-687.	3.5	0
15	Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. <i>World Journal of Surgical Oncology</i> , 2009, 7, 14.	1.9	30
16	Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 415-421.	2.3	22
17	Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2006, 17, 1211-1217.	1.4	18
18	Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. <i>Anti-Cancer Drugs</i> , 2005, 16, 1009-1016.	1.4	39